1. Home
  2. ECVT vs CRVS Comparison

ECVT vs CRVS Comparison

Compare ECVT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ecovyst Inc.

ECVT

Ecovyst Inc.

N/A

Current Price

$10.39

Market Cap

1.3B

Sector

Industrials

ML Signal

N/A

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

N/A

Current Price

$14.91

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ECVT
CRVS
Founded
1935
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2017
2016

Fundamental Metrics

Financial Performance
Metric
ECVT
CRVS
Price
$10.39
$14.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$14.00
$30.17
AVG Volume (30 Days)
1.2M
800.8K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
48.04
EPS
0.11
N/A
Revenue
$723,515,000.00
N/A
Revenue This Year
$29.07
N/A
Revenue Next Year
$6.71
N/A
P/E Ratio
$94.45
N/A
Revenue Growth
2.70
N/A
52 Week Low
$7.41
$5.03
52 Week High
$15.09
$26.95

Technical Indicators

Market Signals
Indicator
ECVT
CRVS
Relative Strength Index (RSI) 30.59 61.02
Support Level $9.67 $14.24
Resistance Level $11.31 $16.66
Average True Range (ATR) 0.40 0.68
MACD -0.13 0.16
Stochastic Oscillator 14.52 86.63

Price Performance

Historical Comparison
ECVT
CRVS

About ECVT Ecovyst Inc.

Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has one operating segment. The Company's single reportable segment, Ecoservices, derives its revenue through the sale of virgin and regenerated sulfuric acid products and services.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: